TruAlt Bioenergy Q2/H1 FY26: Planned Shutdowns for Dual-Feed Transition; CBG Grows 286%; ₹2,250 Cr SAF Plant MOU
TruAlt Bioenergy reported Q2/H1 FY26 results showing short-term dips due to planned dual-feed integration shutdowns. CBG segment saw 286% EBITDA growth. The company also announced a ₹2,250 crore MOU for an ethanol-to-SAF plant.
The impact is high due to the company's significant strategic transformation, including a large-scale dual-feed integration impacting 65% of its capacity for long-term operational benefits. The substantial ₹2,250 crore investment for an SAF plant and the rapid growth of the CBG segment represent major new revenue streams and market positioning, signaling a fundamental shift in the company's future trajectory.
Despite short-term negative financial impacts from planned shutdowns, the overall sentiment is positive due to strategic investments in dual-feed integration for long-term operational efficiency, significant growth in the CBG segment, and a substantial ₹2,250 crore MOU for a Sustainable Aviation Fuel plant, indicating strong future growth prospects and diversification.
TruAlt Bioenergy Limited announced its financial results for the second quarter and first half of the financial year ended September 30, 2025 (Q2 and H1 FY 2025–26). The period was marked by significant transformation: * Operational Transition: The company undertook planned shutdowns and safety-led commissioning activities across three units (1,300 KLPD of its 2,000 KLPD installed capacity) for dual-feed integration. This strategic move aims to shift from a mono-feed, season-linked model to year-round operations, increasing uptime from approximately 140 to 300–330 operating days annually. * Financial Performance (Consolidated H1 FY26 vs H1 FY25): * Revenue from Operations: ₹418.75 crore (down 28%) * Total Income: ₹456.19 crore (down 26%) * Profit After Tax (PAT): (₹33.27 crore) (improved by 17% from ₹40.25 crore loss) * EBITDA: ₹36.99 crore (up 20%) * EBITDA Margin: 8.83% (up 68%) * CBG Segment Breakout Growth: The Compressed Biogas (CBG) segment delivered significant growth in H1 FY26, with income of ₹20.70 crore and PAT of ₹9.71 crore (a 659% surge year-on-year for PAT). EBITDA rose to ₹13.89 crore, marking 286% growth, and EBITDA margins expanded to 68.29%. * Sumitomo Joint Venture: Progress was made on the CBG joint venture with Sumitomo Corporation, following the execution of the Share Purchase Agreement. Four commercial CBG plants are under development, establishing a national CBG network. * Sustainable Aviation Fuel (SAF) Roadmap: TruAlt signed a Memorandum of Understanding (MOU) with the Andhra Pradesh Economic Development Board (APEDB) for a proposed ₹2,250 crore investment to establish an ethanol-to-SAF plant in Andhra Pradesh.
Vijay Nirani, Managing Director, stated that Q2 and H1 FY 2025–26 should be viewed as an investment phase for long-term transformation. He expects sequential improvement in volumes, margins, and cash flows in Q3 and Q4 as the stabilised capacities throughput.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.